Dyspnea

The prevalence of acute myocarditis was low in hospitalized patients with COVID-19 during the first 14 months of the pandemic, researchers reported in Circulation.

Interarterial shunt device (IASD, Corvia Medical) vs. sham procedure in patients with HF with preserved ejection fraction.

Nintedanib reduces the rate of forced vital capacity decline more significantly in patients with systemic sclerosis-associated interstitial lung disease who reported no dyspnea or cough at baseline, data show.

Placement of an atrial shunt device failed to reduce the rate of HF events or improve health status vs. sham in patients with HF with preserved ejection fraction, according to results of the REDUCE LAP-HF II trial published in The Lancet.

Healio and Cardiology Today have aggregated a list of recent updates on the CV impact of COVID-19 infection and vaccination.

History of exacerbations, as well as severity of dyspnea, may predict future exacerbations in patients with COPD, according to results of an observational study published in Respiratory Medicine.

In the top story in cardiology last week, researchers reported that patients hospitalized with COVID-19 developed persistent dyspnea a year after discharge. These patients had no history of heart or lung disease.

Patients who were hospitalized with COVID-19 may have developed cardiac complications as they continued presenting with dyspnea 1 year after hospital discharge, according to a small study presented at EuroEcho 2021.

Patients with severe interstitial lung disease who received heated and humidified nasal high-flow oxygen therapy had significant improvements in endurance, physiologic parameters and sensations during exercise.